CYDY CytoDyn

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT.

CytoDyn CFO, Robert E. Hoffman, will deliver a live company presentation and will be available for one-on-one meetings throughout the event, which is taking place September 8-10, 2025, in New York City.

Details of the presentation are now as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference

Date: September 10, 2025

Time: 9 a.m. EDT

Webcast:

About CytoDyn

CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders.

Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit and follow us on .

Investor Relations

CytoDyn Inc.

Media Contacts

Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.

Russo Partners, LLC



EN
04/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annua...

CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT. CytoDyn CF...

 PRESS RELEASE

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investmen...

CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City. Rob...

 PRESS RELEASE

CytoDyn Announces Encouraging Survival Data in Patients with Metastati...

CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain VANCOUVER, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic in...

 PRESS RELEASE

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Co...

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite st...

 PRESS RELEASE

CytoDyn Releases ESMO Breast Cancer Meeting Poster

CytoDyn Releases ESMO Breast Cancer Meeting Poster VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the Company’s poster presented at the European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting on May 14-17, 2025, in Munich, Germany. A copy of the poster is available at the following link: More information about the data CytoDyn presented at ESMO suggesting the novel mechanis...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch